Loading...
•
Mar 31
Anaptysbio Q1 2025 Earnings Report
AnaptysBio, Inc. reported its financial results for the first quarter ended March 31, 2025, highlighting positive clinical trial results and financial updates.
Key Takeaways
AnaptysBio reported a net loss of $39.3 million for Q1 2025, an improvement from the $43.9 million loss in Q1 2024. The company saw a significant increase in collaboration revenue, reaching $27.8 million, primarily driven by royalties from Jemperli sales and a license agreement with Vanda Pharmaceuticals. Cash and investments decreased to $383.0 million, but the company reiterated its cash runway through year-end 2027.
Rosnilimab achieved positive results in its Phase 2b rheumatoid arthritis trial, with updated data to be presented in June.
Initial Phase 2 data for rosnilimab in ulcerative colitis is on track for Q4 2025.
GSK's Jemperli showed strong commercial performance, leading to increased royalties for AnaptysBio.
AnaptysBio authorized a $75 million stock repurchase program in March 2025 and maintains a cash runway through year-end 2027.
Anaptysbio
Anaptysbio
Forward Guidance
AnaptysBio anticipates several key milestones in its clinical programs and financial collaborations, including further data readouts and potential milestone payments, while maintaining its cash runway.
Positive Outlook
- Updated clinical and translational data for rosnilimab in RA to be presented in early June.
- Initial Phase 2 data for rosnilimab in ulcerative colitis anticipated in Q4 2025.
- ANB033 and ANB101 progressing through Phase 1 trials, with Phase 1b indication for ANB033 to be disclosed at H2 2025 R&D event.
- Anticipate receipt of a $75 million commercial sales milestone payment from GSK once Jemperli achieves $1 billion in worldwide net sales.
- FDA BLA submission for generalized pustular psoriasis (GPP) for imsidolimab expected in 2025.
Challenges Ahead
- No specific negative forward guidance was explicitly stated in the provided text.
- No specific negative forward guidance was explicitly stated in the provided text.
- No specific negative forward guidance was explicitly stated in the provided text.
- No specific negative forward guidance was explicitly stated in the provided text.
- No specific negative forward guidance was explicitly stated in the provided text.